MEDICATIONS AFFECTING THE NERVOUS SYSTEM
Quiz yourself by thinking what should be in
each of the black spaces below before clicking
on it to display the answer.
Help!
|
|
||||
|---|---|---|---|---|---|
| DEPRESSION IS WHAT KIND OF DISORDER | A MOOD/AFFECTIVE
🗑
|
||||
| RELIEF OF SYMPTOMS OF DEPRESSION WITH ANTI-DEPRESSANT THERAPY CAN TAKE HOW LONG | 1-3 WEEKS
🗑
|
||||
| WHEN CAN YOU EXPECT THE FULL BENEFITS OF ANTI-DEPRESSANT THERAPY TO TAKE PLACE | 2-3 MONTHS
🗑
|
||||
| WHAT ARE THE FOUR MAIN GROUPS OF ANTI-DEPRESSANT MEDICATIONS | TCA'S/TRICYCLIC ANTI-DEPRESSANTS
SSRI'S/SELECTIVE SEROTONIN REUPTAKE INHIBITORS
MOAI'S/MONOAMINE OXIDASE INHIBITORS
ATYPICAL ANTIDEPRESSANTS
🗑
|
||||
| WHAT MEDICATIONS ARE UNDER THE CLASSIFICATION OF TCA'S | AMITRIPTYLINE/ELAVIL
IMIPRAMINE/TOFRANIL
DOXEPIN/SINEQUAN
NORTRIPTYLINE/AVENTYL
TRIMIPRAMINE/SURMONTIL
🗑
|
||||
| WHAT IS THE EXPECTED PHARMACOLOGICAL ACTION OF TCA'S | BLOCK REUPTAAKE OF NOREPINEPHRINE AND SEROTONIN IN THE SYNAPTIC SPACE THEREBY INTENSIFYING THE EFFECTS OF THESE NEUROTRANSMITTERS
🗑
|
||||
| WHAT ARE THE THERAPEUTIC EFFECTS OF TCA'S | DEPRESSION
DEPRESSIVE EPISODES OF BIPOLAR DISORDER
CHRONIC PAIN
ENURESIS
🗑
|
||||
| WHAT ARE THE SIDE EFFECTS OF USING TCA'S | ORTHOSTATIC HYPOTENSION
ANTICHOLINERGIC EFFECTS
SEDATION
TOXICITY
DECREASED SEIZURE THRESHOLD
EXCESSIVE SWEATING
🗑
|
||||
| WHAT ARE THE ANTICHOLINERGIC EFFECTS OF TCA'S | DRY MOUTH
BLURRED VISION
PHOTOPHOBIA
URINARY HESITANCY OR RETENTION
CONSTIPATION
TACHYCARDIA
🗑
|
||||
| WHAT KIND OF TOXICITY RESULTS FROM USING TCA'S | CHOLINERGIC BLOCKADE AND CARDIAC TOXICITY EVIDENCED BY
DYSRHYTHMIAS
MENTAL CONFUSION
AGITATION
FOLLOWED BY
SEIZURES
COMA
POSSIBLE DEATH
🗑
|
||||
| TCA'S ARE A PREGNANCY CATEGORY RISK? | C
🗑
|
||||
| TCA'S ARE CONTRAINDICATED IN CLIENTS THAT ? | HAVE SEIZURE DISORDERS
🗑
|
||||
| TCA'S ARE USED CAUTIOUSLY IN CLIENTS WITH | CORONARY ARTERY DISEASE
DIABETES
LIVER DISORDER
KIDNEY DISORDER
RESPIRATORY DISORDER
URINARY RETENTION AND OBSTRUCTION
ANGLE-CLOSURE GLAUCOMA
BENIGN PROSTATIC HYPERTROPHY
HYPERTHYROIDISM
🗑
|
||||
| INTERACTIONS WITH TCA'S INCLUDE | MAOI'S AND ST JOHNS WORT = SEROTONIN SYNDROME
ANTIHISTAMINES = ADDITIVE ANTICHOLINERGIC EFFECTS
TCA'S DECREASE EPHEDRINE, AMPHETAMINE EFFECTS
ALCOHOL, ANTIHISTAMINES, BENZO'S, OPIOIDS = ADDED CNS DEPRESSANT
INCREASED EFFECTS OF EPINEPHRINE, DOPAMINE
🗑
|
||||
| MEDICATIONS CLASSIFIED AS SSRI'S ARE | FLUOXETINE/PROZAC
CITALOPRAM/CELEXA
ESCITALOPRAM/LEXAPRO
PAROXETINE/PAXIL
SERTRALINE/ZOLOFT
🗑
|
||||
| WHAT IS THE EXPECTED PHARMACOLOGICAL ACTION OF SSRI'S | SELECTIVELY BLOCK REUPTAKE OF THE MONOAMINE NEUROTRANSMITTER SEROTONIN IN THE SYNAPTIC SPACE THEREBY INTENSIFYING THE EFFECTS OF SEROTONIN
🗑
|
||||
| THERAPEUTIC USES OF SSRI'S ARE | MAJOR DEPRESSION
OCD
BULIMIA NERVOSA
PMDD
PANIC DISORDER
PTSD
🗑
|
||||
| SIDE EFFECTS OF SSRI'S ARE | SEXUAL DYSFUNCTION
CNS STIMULATION
WEIGHT LOSS (EARLY IN THERAPY)
WEIGHT GAIN (IN LATER THERAPY)
SEROTONIN SYNDROME
WITHDRAWAL SYMPTOMS
HYPONATREMIA
RASH
SLEEPINESS
FAINTNESS
LIGHTHEADEDNESS
GI BLEEDING
BRUXISM
🗑
|
||||
| SEROTONIN SYNDROME MAY BEGIN WHEN | 2-72 HOURS AFTER STARTING THERAPY AND MAY BE LETHAL
🗑
|
||||
| SIDE EFFECTS ASSOCIATED WITH SEROTONIN SYNDROME | MENTAL CONFUSION
DIFFICULTY CONCENTRATING
FEVER
AGITATION
ANXIETY
HALLUCINATIONS
INCOORDINATION
HYPERREFLEXIA
DIAPHORESIS
TREMORS
🗑
|
||||
| WITHDRAWAL SYMPTOMS ASSOCIATED WITH SSRI'S ARE | HEADACHE
NAUSEA
VISUAL DISTURBANCES
ANXIETY
DIZZINESS
TREMORS
🗑
|
||||
| FLUOXETINE IS A PREGNANCY RISK CATEGORY | C
🗑
|
||||
| FLUOXETINE AND PAROXETINE MAY INCREASE THE RISKS OF WHAT | BIRTH DEFECTS
🗑
|
||||
| SSRI'S ARE CONTRAINDICATED IN CLIENTS TAKING | MAOI'S AND TCA'S
🗑
|
||||
| SSRI'S ARE USED CAUTIOUSLY IN CLIENTS WITH | LIVER DYSFUNCTION
RENAL DYSFUNCTION
CARDIAC DISEASE
SEIZURE DISORDERS
DIABETES
ULCERS
HISTORY OF GI BLEEDING
TAKING NSAIDS
TAKING ANTI-COAGULANTS
🗑
|
||||
| MAOI'S AND ST JOHNS WORT INCREASE THE RISK OF | SEROTONIN SYNDROME
🗑
|
||||
| FLUOXETINE CAN DISPLACE WARFARIN/COUMADIN FROM BOUND PROTEIN AND RESULT IN WHAT | INCREASED WARFARIN LEVELS
🗑
|
||||
| FLUOXETINE CAN INCREASE THE LEVELS OF TCA'S AND WHAT | LITHIUM
🗑
|
||||
| FLUOXETINE SUPPRESSES PLATELET AGGREGATION AND THUS INCREASES THE RISK OF BLEEDING WHEN USED WITH WHAT | NSAID'S AND ANTI-COAGULANTS
🗑
|
||||
| MEDICATIONS IN THE MAOI CLASS ARE | PHENELZINE/NARDIL
ISOCARBOXAZID/MARPLAN
TRANYLCYPROMINE/PARNATE
SELEGILINE/EMSAM-TRANSDERMAL MAOI
🗑
|
||||
| THE EXPECTED PHARMACOLOGICAL ACTION OF MAOI'S IS | BLOCK THE MAO-A IN THE BRAIN THEREBY INCREASING THE AMOUNT OF NOREPINEPHRINE, DOPAMINE, SEROTONIN AVAILABLE FOR TRANSMISSION OF IMPULSES THIS INTENSIFIES THE RESPONSE AND RELIEVES DEPRESSION
🗑
|
||||
| THERAPEUTIC USES OF MAOI'S ARE | ATYPICAL DEPRESSION
BULIMIA NERVOSA
OCD
🗑
|
||||
| SIDE EFFECTS OF MAOI'S INCLUDE | CNS STIMULATION
ORTHOSTATIC HYPOTENSION
HYPERTENSIVE CRISIS
LOCAL RASH WITH TRANSDERMAL USE
🗑
|
||||
| WHAT ARE THE SPECIFIC SIDE EFFECTS ASSOCIATED WITH THE CNS STIMULATION | ANXIETY
AGITATION
MANIA
HYPOMANIA
🗑
|
||||
| WHAT CAUSES THE HYPERTENSIVE CRISIS ASSOCIATED WITH USE OF MAOI'S | TYRAMINE CONTAINING FOODS
🗑
|
||||
| WHAT ARE THE SIDE EFFECTS OF HYPERTENSIVE CRISIS ASSOCIATED WITH THE USE OF TYRAMINES AND MAOI'S | HEADACHE
NAUSEA
INCREASED HEART RATE
INCREASED BLOOD PRESSURE
🗑
|
||||
| MAOI'S ARE PREGNANCY RISK CATEGORY | C
🗑
|
||||
| MAOI'S ARE CONTRAINDICATED IN WHAT TYPE OF CLIENTS | TAKING SSRI'S
THOSE WITH PHEOCHROMOCYTOMA
CARDIOVASCULAR DISEASE
CEREBRAL VASCULAR DISEASE
SEVERE RENAL INSUFFICENCY
🗑
|
||||
| MAOI'S ARE USED CAUTIOUSLY IN CLIENTS WITH | DIABETES
SEIZURE DISORDERS
TAKING TCA'S
🗑
|
||||
| TRANSDERMAL SELEGILINE/EMSAM IS CONTRAINDICATED IN CLIENTS TAKING | CARBAMAZEPINE/TEGRETOL
OXCARBAZEPINE/TRILEPTAL
WHICH MAY INCREASE THE BLOOD LEVELS OF THE MAOI
🗑
|
||||
| INTERACTIONS WITH MAOI'S | INDIRECT ACTING SYMPATHOMIMETIC MEDICATIONS
TCA'S
SSRI'S
MEPERIDINE/DEMEROL
TYRAMINE RICH FOODS
VASOPRESSORS
🗑
|
||||
| INDIRECT ACTING SYMPATHOMIMETIC MEDICATIONS PROMOTE THE RELEASE OF NOREPINEPHRINE AND CAN LEAD TO WHAT | HYPERTENSIVE CRISIS
🗑
|
||||
| USE OF TCA'S AND MAOI'S CAN LEAD TO WHAT | HYPERTENSIVE CRISIS
🗑
|
||||
| USE OF SSRI'S AND MAOI'S CAN LEAD TO WHAT | SEROTONIN SYNDROME
🗑
|
||||
| ANTIHYPERTENSIVES AND MAOI'S HAVE A ADDITIVE WHAT EFFECT | HYPOTENSIVE
🗑
|
||||
| MEPERIDINE/DEMEROL AND MAOI'SCAN LEAD TO WHAT | HYPERPYREXIA
🗑
|
||||
| CONCURRENT USE OF VASOPRESSORS AND MAOI'S RESULT IN WHAT | HYPERTENSION
🗑
|
||||
| WHAT ARE MEDICATIONS THAT ARE LISTED AS ATYPICAL ANTIDEPRESSANTS | BUPROPRION HCL/WELLBUTRIN
🗑
|
||||
| WHAT IS THE EXPECTED PHARMACOLOGICAL ACTION OF ATYPICAL ANTI-DEPRESSANTS | INHIBITING DOPAMINE UPTAKE
🗑
|
||||
| THERAPEUTIC USES OF ATYPICAL ANTI-DEPRESSANTS ARE | TREATMENT OF DEPRESSION
ALTERNATIVE TO SSRI'S FOR CLIENTS UNABLE TO TOLERATE SEXUAL DYSFUNCTION SIDE EFFECTS OF SSRI'S
AID TO QUIT SMOKING
PREVENTION OF SAD
🗑
|
||||
| SIDE EFFECTS OF ATYPICAL ANTI-DEPRESSANTS | HEADACHE
DRY MOUTH
GI DISTRESS
CONSTIPATION
INCREASED HEART RATE
NAUSEA
RESTLESSNESS
INSOMNIA
SUPRESSION OF APPETITE
WEIGHT LOSS
SEIZURES
🗑
|
||||
| BUPROPRION HCL/WELLBUTRIN IS A PREGNANCY RISK CATEGORY WHAT | B
🗑
|
||||
| ATYPICAL ANTI-DEPRESSANTS ARE CONTRAINDICATED IN CLIENTS THAT ARE | TAKING MAOI'S
🗑
|
||||
| ATYPICAL ANTI-DEPRESSANTS ARE USED CAUTIOUSLY IN CLIENTS WHO HAVE | SEIZURE DISORDERS
🗑
|
||||
| ATYPICAL ANTI-DEPRESSANTS INTERACT WITH MAOI'S AND INCREASE THE RISK OF | TOXICITY
🗑
|
||||
| OTHER ATYPICAL ANTIDEPRESSANTS ARE | VENLAFAXINE/EFFEXOR
DULOXETINE/CYMBALTA (SNRI'S)
MIRTAZAPINE/REMERON
REBOXETINE/EDRONAX
TRAZADONE/DESYREL
🗑
|
||||
| EFFEXOR AND CYMBALTA'S PHARMACOLOGICAL ACTION IS | INHIBIT SEROTONIN AND NOREPINEPHRINE REUPTAKE THEREBY INCREASING THE AMOUNT OF THESE NEUROTRANSMITTERS AVAILABLE IN BRAIN IMPULSE TRANSMISSION
🗑
|
||||
| MIRTAZAPINE/REMERON'S PHARMACOLOGICAL ACTION | INCREASE RELEASE OF SEROTONIN AND NOREPINEPHRINE AND THEREBY INCREASING THE AMOUNT OF NEUROTRANSMITTERS AVAILABLE FOR IMPULSE TRANSMISSION
🗑
|
||||
| REBOXETINE/EDRONAX'S PHARMACOLOGICAL ACTION | SELECTIVELY INHIBITS THE REUPTAKE OF NOREPINEPHRINE THEREBY INCREASING THE AMOUNT OF NEUROTRANSMITTERS AVAILABLE FOR IMPULSE TRANSMISSION
🗑
|
||||
| TRAZADONE/DESYREL'S PHARMACOLOGICAL ACTION | HAS MODERATE SELECTIVE BLOCKADE OF SEROTONIN RECEPTORS WHICH ALLOWS MORE SEROTONIN TO BE AVAILABLE FOR IMPULSE TRANSMISSION
🗑
|
Review the information in the table. When you are ready to quiz yourself you can hide individual columns or the entire table. Then you can click on the empty cells to reveal the answer. Try to recall what will be displayed before clicking the empty cell.
To hide a column, click on the column name.
To hide the entire table, click on the "Hide All" button.
You may also shuffle the rows of the table by clicking on the "Shuffle" button.
Or sort by any of the columns using the down arrow next to any column heading.
If you know all the data on any row, you can temporarily remove it by tapping the trash can to the right of the row.
To hide a column, click on the column name.
To hide the entire table, click on the "Hide All" button.
You may also shuffle the rows of the table by clicking on the "Shuffle" button.
Or sort by any of the columns using the down arrow next to any column heading.
If you know all the data on any row, you can temporarily remove it by tapping the trash can to the right of the row.
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Created by:
nursebtanner
Popular Nursing sets